M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover PharmaphorumRepligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.Read full story pharminent July 22, 2026 (Last updated: July 22, 2026) Pharmaphorum Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed. Read full story Post navigation Previous: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028Next: Samsung Biologics: geographic diversification is a sound business decision Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026